Global Folliculitis Market Size, Share, Forecast Report, 2020-2027

Folliculitis is very common health problems across the globe. About 3 million cases found per year in the US alone. Folliculitis can be noninfectious or infectious. Although, most of the cases of folliculitis are infectious. Increasing knowledge of folliculitis, rapid adoption of products, and increasing healthcare expenditure are driving this market. Emerging economies account for a major share of the global folliculitis market which is expected to grow at the CAGR of ~4.7% during the forecast period and is estimated to reach USD 561.3 million by 2023.
Segments:

Global folliculitis market has been segmented on the basis of type which comprise superficial folliculitis, deep folliculitis, and others. Superficial folliculitis is sub-segmented into bacterial folliculitis, hot tub folliculitis (pseudomonas folliculitis), barber's itch (pseudofolliculitis barbae), pityrosporum folliculitis. Deep folliculitis is sub-segmented into sycosis barbae, gram-negative folliculitis, boils (furuncles) and carbuncles, eosinophilic folliculitis.

On the basis of treatments, the market has been segmented into medication, warm compress, medicated shampoo, and others. Medication is sub-segmented into antibiotics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), antifungals, antivirals, and others.

On the basis of end user, it is segmented into hospitals and clinics, medical research centers, academic institutes, and others.
Key players for global folliculitis market:

Some of the key players in this market are: AbbVie Inc. (US), Allergan (Republic of Ireland), AstraZeneca (UK), CELGENE CORPORATION (US), GlaxoSmithKline plc. (UK), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Pfizer Inc.(US), and others.